April 25, 2019
Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com. The Annual Report is found here.
For further information, please contact:
Per Persson, CEO
Phone: +46 73 600 59 90
Acarix is listed on Nasdaq First North in Stockholm. Wildeco Ekonomisk Information AB (+46 8 545 271 00, email@example.com) is Certified Adviser to Acarix. This information is such that Acarix (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 25, 2019 at 08.00 (CET).
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.